Our work in drug-resistant TB
The Union advocates for increased research and development, and conducts clinical trials to reduce treatment time and improve outcomes for patients in countries with the highest burdens of disease.
The Union also provides practical and experience-based support to countries implementing care for people with DR-TB. Our expertise is based on our extensive research with partners supporting the nine-month regimen, including partnering on the first randomised control trial into a new regimen for multidrug-resistant TB (TREAT TB).
With the new World Health Organization guidelines focusing on shorter, all oral, regimens for MDR-TB, The Union continues to support countries to implement the latest evidence-based treatments.
TREAT TB
Read more about TREAT TB (Technology, Research, Education and Technical Assistance for Tuberculosis), an ambitious initiative that was launched by The Union, seeking to contribute new knowledge regarding shorter, more tolerable treatment regimens for MDR-TB.
OTHER AREAS OF OUR WORK IN TUBERCULOSIS
You might also be interested in our work on child and adolescent TB and TB-HIV, TB-diabetes and co-morbidities.
The Union used an operational research approach to test a shortened treatment regimen for multidrug-resistant TB. The study first demonstrated a greater than 80% success rate in Bangladesh, Cameroon and Niger and The Union continued to work to develop and implement shorter more effective regimens for the treatment of MDR-TB.
Learn more
Understand the issues with our fact sheets
DR-TB Union news
The latest TB R&D developments must pave the way for greater investment
Last week saw critical announcements on tuberculosis research and development, which show important progress in the field. The Union calls for greater knowledge and data sharing to ensure that scientific research can have the biggest impact in the fight to end TB.
Union Guide is blueprint for national TB guidelines around the world
Seventh edition of The Union’s popular technical guide ‘Management of Tuberculosis: A Guide to Essential Practice’ now available in French and Spanish.
Bedaquiline: Rolling out the first new TB drug since 1960
A special thematic issue of The Union's International Journal of Tuberculosis and Lung Disease explores increasing access to this vital treatment for multidrug-resistant TB.
Union statement on the 2020 WHO Global TB Report
The latest Global Tuberculosis Report has been launched by the World Health Organization. José Luis Castro, Executive Director of The Union responds.